Drugs / Huperzine A
Trials 14
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06570655 | May → Jun 2024 | — | Wanbangde Pharmaceutical Group Co., LTD | Completed | No outcome recorded |
| Phase 1 | NCT03156439 | May → Sep 2017 | complex partial epilepsy | Supernus Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03474770 | Apr 2018 → Dec 2026 expected | focal epilepsy | Supernus Pharmaceuticals, Inc. | Active not recruiting | No outcome recorded |
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT01676311 | Dec 2013 → Aug 2018 | traumatic brain injury | Spaulding Rehabilitation Hospital | Terminated | Missed primary Stop: Enrollment |
| Phase 2 | NCT00083590 | Apr 2004 → Nov 2007 | Alzheimer disease | National Institute on Aging (NIA) | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT07066826 | Aug 2025 → Aug 2028 expected | Alzheimer disease | Wanbangde Pharmaceutical Group Co., LTD | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT01282619 | May 2010 → Jun 2012 | Alzheimer disease | Shandong Luye Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 44 trials | ||||||
| Phase 4 | NCT06704334 | Apr 2024 → Dec 2026 expected | cognitive impairment with or without cerebellar ataxia | Wanbangde Pharmaceutical Group Co., LTD | Recruiting | No outcome recorded |
| Phase 4 | NCT05560373 | Sep 2022 → Sep 2024 | — | Wanbangde Pharmaceutical Group Co., LTD | Unknown | No outcome recorded |
| Phase 4 | NCT04509323 | Aug 2020 → Feb 2021 | — | Jiangsu Famous Medical Technology Co., Ltd. | Unknown | No outcome recorded |
| Phase 4 | NCT01012830 | Dec 2009 → Dec 2010 | dementia, schizophrenia | VA Nebraska Western Iowa Health Care System | Unknown | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT05242419 | Jun 2022 → Nov 2025 overdue | delirium | Second Affiliated Hospital of Wenzhou Medical University | Recruiting | No outcome recorded |
| — | NCT03101722 | May 2017 → Sep 2030 expected | cognitive impairment with or without cerebellar ataxia, presbycusis, tinnitus | Zhijun Bao | Enrolling by invitation | No outcome recorded |
| — | NCT01136551 | Sep 2010 → Jan 2011 | — | Hadassah Medical Organization | Unknown | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT01030692 Comparator | Jan 2009 → Jun 2014 | cocaine abuse, cocaine dependence | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT02931136 Comparator | Nov 2019 → Dec 2024 | cognitive impairment with or without cerebellar ataxia | Shanghai Mental Health Center | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-05-23 | Supernus Pharmaceuticals, Inc. | Results Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy supernus.com ↗
today announced data from the planned interim analysis of the exploratory open-label Phase 2a clinical study of SPN-817 for treatment-resistant seizures. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-05-23 | Supernus Pharmaceuticals, Inc. | Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy supernus.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 17 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | huperzine A | “comparison of huperzine A sustained-release tablets 400µg once a day, huperzine A tablets 200µg twice a day, and placebo.” NCT01282619 ↗16“BIS-001 ER is an extended release formulation of the nutritional supplement Huperzine A.” NCT03474770 ↗ “BIS-001 ER is an extended release formulation of the nutritional supplement Huperzine A.” NCT03156439 ↗ |
| Known as | (-)-selagine | ChEMBL registry synonym — accepted as the source's own label CHEMBL395280 ↗ |
| Known as | L-huperzine a | ChEMBL registry synonym — accepted as the source's own label CHEMBL395280 ↗ |
| Action | Inhibit | “Huperzine A is a natural cholinesterase inhibitor derived from the Chinese herb Huperzia serrata.” NCT00083590 ↗1“Acetylcholinesterase inhibitor” CHEMBL395280 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “Chinese herb huperzine A” NCT00083590 ↗ |
| Route | Oral | “between cocaine and oral huperzine A (HupA)” NCT01030692 ↗ |
| Target | ACHE | “Acetylcholinesterase inhibitor” CHEMBL395280 ↗ |